Laboratory for Cancer Immunotherapy, Department of Biomedicine and Medical Oncology, Department of Internal Medicine, University Hospital, Basel, Switzerland.
Department of Physiology, University of Zurich, Zurich, Switzerland.
Front Immunol. 2019 Sep 6;10:2120. doi: 10.3389/fimmu.2019.02120. eCollection 2019.
Cell-cell interactions and cell adhesion are key mediators of cancer progression and facilitate hallmarks of cancer including immune evasion and metastatic dissemination. Many cell adhesion molecules within the tumor microenvironment are changed and significant alterations of glycosylation are observed. These changes in cell adhesion molecules alter the ability of tumor cells to interact with other cells and extracellular matrix proteins. Three families of cell-cell interaction molecules selectins, Siglecs, and integrins have been associated with cancer progression in many pre-clinical studies, yet inhibition of cell adhesion as a therapeutic target is just beginning to be explored. We review how cell-cell interactions mediated by integrins and the glycan-binding receptors selectins and Siglec receptors support cancer progression. The discussion focuses on mechanisms during immune evasion and metastasis that can be therapeutically targeted by blocking these cell-cell interactions.
细胞-细胞相互作用和细胞黏附是癌症进展的关键介质，有助于癌症的标志性特征，包括免疫逃逸和转移扩散。肿瘤微环境中的许多细胞黏附分子发生改变，并观察到糖基化的显著改变。这些细胞黏附分子的变化改变了肿瘤细胞与其他细胞和细胞外基质蛋白相互作用的能力。在许多临床前研究中，细胞-细胞相互作用分子选择素、Siglecs 和整合素的三个家族与癌症进展相关，但作为治疗靶点的细胞黏附抑制作用才刚刚开始被探索。我们回顾了整合素介导的细胞-细胞相互作用以及糖基结合受体选择素和 Siglec 受体如何支持癌症进展。讨论重点是免疫逃逸和转移过程中的机制，这些机制可以通过阻断这些细胞-细胞相互作用来进行治疗靶向。
